Trials / Conditions / Advanced Solid Tumors Cancer

Advanced Solid Tumors Cancer

19 registered clinical trials studyying Advanced Solid Tumors Cancer — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	First-In-Human Study of KHN922 for Injection NCT07514975	Chengdu Kanghong Biotech Co., Ltd.	Phase 1 / Phase 2
Recruiting	A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12 NCT07259590	Genfleet Therapeutics (Shanghai) Inc.	Phase 1 / Phase 2
Recruiting	PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer NCT07190469	ProteinQure Inc.	Phase 1
Not Yet Recruiting	A Study of KC1086 in Patients With Advanced Solid Tumors NCT07118709	Beijing Konruns Pharmaceutical Co., Ltd.	Phase 1
Recruiting	Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies NCT07327489	Elephas	—
Recruiting	A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. NCT06898450	Nimbus Wadjet, Inc.	Phase 1 / Phase 2
Recruiting	ORB-021 In Patients With Advanced Solid Tumors NCT06607939	Orionis Biosciences Inc	Phase 1
Completed	Biological Age Predicts 90-Day Mortality in Advanced Cancer NCT07035470	Ankara Etlik City Hospital	—
Active Not Recruiting	Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Eve NCT04721015	AbbVie	Phase 1
Completed	First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanc NCT04417465	AbbVie	Phase 1
Completed	A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Til NCT04196283	AbbVie	Phase 1
Active Not Recruiting	Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmonipl NCT03821935	AbbVie	Phase 1
Completed	A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors NCT03311477	AbbVie	Phase 1
Completed	A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced NCT03234712	AbbVie	Phase 1
Terminated	A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced NCT03145909	AbbVie	Phase 1
Completed	A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subj NCT03071757	AbbVie	Phase 1
Active Not Recruiting	A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors NCT02988960	AbbVie	Phase 1
Completed	A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors NCT02955251	AbbVie	Phase 1
Active Not Recruiting	A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants Wit NCT02099058	AbbVie	Phase 1